Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Objective assessment (prolactin levels, ng/ml) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE/FGA (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychopathology ‐ various scales · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Adverse effects: Extrapyramidal symptoms (Simpson‐Angus) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes prodromal symptoms: transition to psychosis Endpoint data, (events)… compared with placebo + supportive intervention (very low certainty).
1 finding from 1 review
Global effect: 1a. Medium‐term ‐ Average end point score on various outcomes ‐ CGI‐severity (low = favourable) ( · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state: psychosis risk symptoms SOPS total (higher score = worse, scale from: 0‐114) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Weight gain · people in the prodromal stage of psychosis
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes satisfaction with treatment: leaving the study early Endpoint data… compared with placebo + supportive intervention (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ vs olanzapine ‐ medium term As defined in each study · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: no improvement ‐ vs olanzapine ‐ medium term As… compared with antipsychotics (very low certainty).
1 finding from 1 review
No improvement (clozapine vs olanzapine) · people with psychosis
1 finding from 1 review
Drug‐induced diabetes (clozapine vs olanzapine) · people with psychosis
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis
1 finding from 1 review
No improvement (risperidone vs olanzapine) · people with psychosis
1 finding from 1 review